Robert Langreth

1 day ago | news.bloombergtax.com | Madison Muller |Robert Langreth |Ike Swetlitz

A new class of weight-loss drugs known as GLP-1s have proved to be game changers for people with obesity. They’re also minting billions of dollars for the pharmaceutical companies that developed them, Eli Lilly & Co. and Novo Nordisk A/S. The high prices for these drugs along with spotty insurance coverage have left them out of reach for many Americans. That’s beginning to change, however, as Lilly and Novo offer discounted versions to patients whose insurance doesn’t cover the medications.

1 day ago | news.bloomberglaw.com | Madison Muller |Robert Langreth |Ike Swetlitz

A new class of weight-loss drugs known as GLP-1s have proved to be game changers for people with obesity. They’re also minting billions of dollars for the pharmaceutical companies that developed them, Eli Lilly & Co. and Novo Nordisk A/S. The high prices for these drugs along with spotty insurance coverage have left them out of reach for many Americans. That’s beginning to change, however, as Lilly and Novo offer discounted versions to patients whose insurance doesn’t cover the medications.

1 day ago | bloomberg.com | Madison Muller |Robert Langreth |Ike Swetlitz

Wegovy and Zepbound have revolutionized the treatment of obesity.  (Bloomberg Businessweek) -- A new class of weight-loss drugs known as GLP-1s have proved to be game changers for people with obesity. They’re also minting billions of dollars for the pharmaceutical companies that developed them, Eli Lilly & Co. and Novo Nordisk A/S. The high prices for these drugs along with spotty insurance coverage have left them out of reach for many Americans.

1 week ago | news.bloomberglaw.com | Robert Langreth |Madison Muller |Ike Swetlitz

The obesity drug price wars are finally starting. After being publicly lambasted for the high cost of their weight-loss shots, two of world’s biggest drugmakers — Eli Lilly & Co. and Novo Nordisk A/S — are racing to lock up deals with drug benefit managers that control which prescriptions many Americans get and popular telehealth companies that sell directly to consumers. Investors are worried about how low prices will go.

1 week ago | news.bloombergtax.com | Robert Langreth |Madison Muller |Ike Swetlitz

The obesity drug price wars are finally starting. After being publicly lambasted for the high cost of their weight-loss shots, two of world’s biggest drugmakers — Eli Lilly & Co. and Novo Nordisk A/S — are racing to lock up deals with drug benefit managers that control which prescriptions many Americans get as well as popular telehealth companies that sell directly to consumers. Investors are worried about how low prices will go.